Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment

The absence of potent therapeutic option accounts for the dismal prognosis of advanced hepatocellular carcinoma (HCC) with high mortality and recurrence rate. For a decade, sorafenib is the only approved systemic drug in the first-line setting and warrants as the standard-of-care for HCC in the adva...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Gastroenterol Hepatol
Main Authors: Siu, Elaine Hon-Lam, Chan, Anthony Wing-Hung, Chong, Charing Ching-Ning, Chan, Stephen Lam, Lo, Kwok-Wai, Cheung, Siu Tim
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2018
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6286919/
https://ncbi.nlm.nih.gov/pubmed/30603725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tgh.2018.10.16
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados